A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma

Overview of attention for article published in Clinical Cancer Research, September 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (93rd percentile)
Good Attention Score compared to outputs of the same age and source (76th percentile)

So far, Altmetric has seen 40 tweets from 30 users, with an upper bound of 33,790 followers.

RT @CCR_AACR: #Lenvatinib plus #eribulin is safe, has manageable side effects and promising efficacy in patients with advanced #leiomyosarc…

RT @CCR_AACR: #Lenvatinib plus #eribulin is safe, has manageable side effects and promising efficacy in patients with advanced #leiomyosarc…

RT @CCR_AACR: #Lenvatinib plus #eribulin is safe, has manageable side effects and promising efficacy in patients with advanced #leiomyosarc…

RT @CCR_AACR: #Lenvatinib plus #eribulin is safe, has manageable side effects and promising efficacy in patients with advanced #leiomyosarc…

This page shows the most recent tweets that mention this research output.

Click here to find out how to access more activity, including 36 additional tweets.